Casa
asdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso

Descrição
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Monthly improvements in paid work productivity: ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
POS0229 DISEASE ACTIVITY AND INFLAMMATION FOLLOWING WITHDRAWAL OF CERTOLIZUMAB PEGOL TREATMENT IN AXIAL SPONDYLOARTHRITIS PATIENTS WHO DID NOT EXPERIENCE FLARES DURING THE C-OPTIMISE STUDY
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison - Document - Gale OneFile: Health and Medicine
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF‐alpha inhibitors for ankylosing spondylitis - Maxwell, LJ - 2015
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
THU0379 REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWING ONE YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL: 48-WEEK INTERIM RESULTS FROM A 96-WEEK OPEN-LABEL STUDY
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study - The Lancet
de por adulto (o preço varia de acordo com o tamanho do grupo)